Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled double blind trial of inhaled AZD1419 in adults with eosinophilic moderate to severe asthma
2016-000977-19Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD1419 inhalation with Placebo inhalation (2 arms). Primary endpoint: Time to loss of asthma control. Started Jun 2016; status: completed.
02
Drugs
azd1419
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-000977-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000977-19.